12 terminated. 12 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Terminated 12 |
| Phase 1 | 2 | Terminated 2 |
Follow Chronic Urticaria: new trials by email Literature Review of Chronic Urticaria trials Research Report on Chronic Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment - Chronic Urticaria, Idiopathic, Hidradenitis | Phase 2 | Terminated | InflaRx GmbH | 73 | 2025-01-02 | 2026-02-03 |
| A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials Briquilimab - Urticaria Chronic | Phase 2 | Terminated | Jasper Therapeutics, Inc. | 67 | 2024-11-26 | 2026-08-06 |
| A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines Briquilimab - Chronic Inducible Urticaria | Phase 1 / Phase 2 | Terminated | Jasper Therapeutics, Inc. | 27 | 2024-03-18 | 2025-10-08 |
| Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria Oral EP262, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Terminated | Escient Pharmaceuticals, Inc | 113 | 2023-09-25 | 2025-12-19 |
| A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria Lirentelimab (AK002), Placebo - Chronic Spontaneous Urticaria | Phase 2 | Terminated | Allakos Inc. | 127 | 2022-10-26 | 2024-09-27 |
| A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) Benralizumab, Placebo and Benralizumab - Chronic Spontaneous Urticaria | Phase 2 | Terminated | AstraZeneca | 159 | 2020-10-27 | 2024-03-13 |
| Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) ATI-450 - Cryopyrin-Associated Periodic Syndrome | Phase 2 | Terminated | Aclaris Therapeutics, Inc. | 1 | 2020-10-23 | 2023-09-21 |
| A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria LY3454738, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Terminated | Eli Lilly and Company | 52 | 2019-11-15 | 2022-03-11 |
| HL2351 CAPS Phase II Study HL2351 - Cryopyrin-Associated Periodic Syndromes (CAPS) | Phase 2 | Terminated | Handok Inc. | 8 | 2015-10-01 | 2017-01-04 |
| Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria Miltefosine, Placebo - Chronic Urticaria | Phase 2 | Terminated | Marcus Maurer | 76 | 2008-09-01 | 2016-12-26 |
| Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease anakinra - Nervous System Malformations, Arthropathy, Neurogenic | Phase 1 / Phase 2 | Terminated | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 43 | 2003-09-01 | 2016-12-01 |
| A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic Urticaria Methotrexate (drug), placebo capsules - Urticaria | Phase 2 | Terminated | Barnsley Hospital | 3 | 2003-08-01 | 2016-02-19 |
Urticaria (7) · Cryopyrin-Associated Periodic Syndromes (3) · Pruritus (3) · Arthropathy, Neurogenic (1) · Chronic Inducible Urticaria (1) · Congenital Abnormalities (1) · Hidradenitis (1) · Hidradenitis Suppurativa (1) · Immune System Diseases (1) · Joint Diseases (1) · Nervous System Malformations (1) · Papilledema (1) · Skin Diseases (1) · Skin Diseases, Vascular (1)
Chronic Disease (12) · Disease Attributes (12) · Hypersensitivity (12) · Hypersensitivity, Immediate (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Skin and Connective Tissue Diseases (12) · Immune System Diseases (11) · Skin Diseases (11) · Skin Diseases, Vascular (11) · Urticaria (5) · Chronic Inducible Urticaria (3) · Cold Urticaria (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)
AK002 (1) · Interleukin 1 Receptor Antagonist Protein (1) · Methotrexate (1) · Pharmaceutical Preparations (1) · Therapeutics (1) · benralizumab (1) · miltefosine (1)
Jasper Therapeutics, Inc. (2) · Aclaris Therapeutics, Inc. (1) · Allakos Inc. (1) · AstraZeneca (1) · Barnsley Hospital (1) · Eli Lilly and Company (1) · Escient Pharmaceuticals, Inc (1) · Handok Inc. (1) · InflaRx GmbH (1) · Marcus Maurer (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)
Germany (8) · United States (8) · Poland (5) · Bulgaria (2) · South Korea (2) · Spain (2) · Canada (1) · Georgia (1) · Greece (1) · Japan (1) · Netherlands (1)
Chin Lee, MD, MPH (1) · David Gordon (1) · Markus Magerl, MD (1) · Raphaela T Goldbach-Mansky, M.D. (1) · Ruth A Sabroe, FRCP, MD (1) · Sabine Altrichter, MD (1)
PMID 16899778, PMID 22294344, PMID 25223501, PMID 27143789, PMID 28118536
2019 (1), 2023 (1), ZIAAR041138-08 (1)